ArticleUrology research & practice2025
Expression of Platelet-Derived Growth Factor Alpha and Beta Receptors in Primary Tumor Cells of Patients with Renal Cell Carcinoma.
Article in Urology research & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the expression of platelet-derived growth factor receptors alpha and beta (PDGFR!/") in primary tumor cells of patients with renal cell carcinoma (RCC). Methods: Platelet-derived growth factor receptors alpha and beta expression was analyzed in RCC specimens from 65 RCC patients (pT1a-T4NanyMany) using immunohis- tochemistry. Expression levels were quantified using the semi-quantitative H-score (HS) method, and correlations between PDGFR!/" expression and tumor characteris- tics were evaluated. The impact of PDGFR!/" expression on patient survival was also examined. Results: Platelet-derived growth factor receptor alpha was expressed in the cytoplasm and membrane of 58.5% of primary RCC cells, with an HS of 62.9 ± 8.4, significantly higher than PDGFR" expression (44.6%; 26.6 ± 5.3; P > .05). Platelet-derived growth factor receptor alpha expression correlated with tumor grade (r = 0.471; P < .0001) and the pN+ category (r = 0.280; P = .024). Platelet-derived growth factor receptor beta expression correlated with tumor grade (r = 0.286; P = .021), venous tumor thrombosis (r = 0.263; P = .034), M+ category (r = 0.305; P = .014), and adrenal metastases (r = 0.306; P = .041). Neither PDGFR! nor PDGFR" expression levels influenced patient survival. Conclusion: Platelet-derived growth factor receptor alpha was more highly expressed in RCC cells compared to PDGFR". Overexpression of PDGFR!/" was associated with higher tumor grade and advanced RCC stages, though it did not affect patient survival.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.